Navigation Links
WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
Date:8/9/2009

SHANGHAI, Aug. 9 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on August 7, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class B directors Xuesong Leng, Zhaohui Zhang, and Ning Zhao, each to serve a three-year term.

In addition, the WuXi shareholders approved an amendment to the Company's Memorandum of Articles and Association that revises Article 82 so that it no longer requires a Special Resolution be obtained for an office of a Director to be considered vacated.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.
     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
2. WuXi PharmaTech Receives Award from BASF
3. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
4. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
5. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
6. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
7. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
8. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
9. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
10. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
11. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):